Vaso Corporation Reports 8% Revenue Growth to $11.2 Million in Q2 2026

Vaso Corporation reported its financial results for the second quarter of 2026, revealing total revenues of $11.2 million, an increase of 8% from $10.3 million in the same period last year. The professional sales services segment, which focuses on healthcare capital equipment sales, saw a significant rise in commission revenues, reaching $10.5 million, up 20% from $8.7 million in the prior year. The equipment segment also contributed to the revenue growth, with sales increasing by 31% to $693,000, driven primarily by higher equipment deliveries in China. However, the IT segment reported no revenue due to the divestiture of its operations, including the sale of NetWolves, which was completed on July 31, 2026.

The company's gross profit for the quarter was $8.9 million, representing 79% of total revenue, compared to $7.9 million, or 77% of revenue, in the previous year. This increase in gross profit was attributed to higher commission revenues and lower blended commission costs in the professional sales services segment. Operating income surged to $974,000, a substantial increase from $93,000 in the same quarter of 2025, primarily due to the rise in gross profit, despite a slight increase in selling, general, and administrative expenses.

In terms of operational metrics, Vaso's cash and cash equivalents rose to $38.3 million as of June 30, 2026, compared to $34.1 million at the end of 2025. The company reported a net loss of $343,000 for the first half of 2026, a significant improvement from a loss of $1.3 million in the same period last year. The reduction in net loss was attributed to improved operating performance and a decrease in losses from discontinued operations. The company also noted an increase in deferred revenue, which stood at $41.5 million, reflecting a higher volume of new orders compared to delivered equipment.

Looking ahead, Vaso Corporation anticipates continued growth in its professional sales services and equipment segments, supported by its exclusive sales representation agreement with GE Healthcare, which has been extended through December 2030. The company expects to generate sufficient cash flow from operations to meet its obligations over the next twelve months. However, it remains cautious about potential market risks, including economic conditions and competitive pressures in the healthcare technology sector.